View all veterinary jobs
The poster, by Lucy Williams BVSc MRCVS, Marketing and Veterinary Technical Services Manager at Carus Animal Health, Tristan Cogan BSc (Hons) PhD FHEA FRSBHE, Christina Maunder BVM&S CertSAM DipECVIM-CA FRCVS FHEA, Helen Howell PhD DSc (Hons) from Bristol Veterinary School, was based on a study from Carus Animal Health and the University of Bristol.
Data presented at VOACON demonstrated that faecal calprotectin was elevated in some dogs receiving oral NSAIDs, even in the absence of obvious GI signs.
The findings build on previous validation work from the University of Bristol.
The research was conducted using GIQuest, Carus Animal Health's patient-side faecal calprotectin test.
Lucy said: "Veterinary teams are becoming increasingly proactive in how they manage osteoarthritis patients.
"We know NSAIDs can have a hugely positive impact on quality of life, but clinicians are also looking for ways to monitor patients more closely and identify potential issues before they become clinically significant.
"The response to this research at VOACON reflects the profession's growing interest in objective biomarkers that can support more informed treatment decisions and enhance patient care."
Jolian Howell, Chief Business Officer and Director of Carus Animal Health, said: "This award is a significant achievement, not only for Carus but also for the wider field of gastrointestinal biomarker research. It recognises the value of building an evidence base around earlier detection, patient monitoring and preventive healthcare.
https://carusanimalhealth.com/giquest
The company makes GIQuest, a patient-side lateral flow faecal calprotectin test, which it says can be used to guide next steps in dogs and cats with chronic GI conditions, including chronic enteropathy (CE; previously IBD), food responsive enteropathy (FRE) and GI side-effects associated with NSAID use.
Carus says that a validation study conducted at the University of Bristol has shown that its GIQuest can reliably distinguish dogs and cats with inflammatory enteropathy from healthy controls, with high sensitivity and specificity.
The company says faecal calprotectin is already well established in human medicine as a non-invasive marker of intestinal inflammation and is increasingly being adopted in veterinary practice to support diagnostic decision-making and treatment monitoring.
Lucy Williams MRCVS, from Carus Animal Health, said: “Individual case experiences often highlight nuances that don’t always come through in formal studies.
"Bringing these together can help illustrate how faecal calprotectin testing is being applied in different clinical scenarios, from refining diagnostic pathways to supporting monitoring and owner communication.
"By sharing practical insights from everyday cases, the profession can collectively build confidence around when and how this tool is most useful in practice.”
Case studies can be submitted by both veterinary surgeons and veterinary nurses and may include, but are not limited to: dogs or cats with chronic or recurrent GI signs, suspected inflammatory enteropathies, monitoring response to dietary or treatment trials or identification of GI inflammation in patients receiving long term oral NSAIDs.
As a thank you for taking part, the five strongest submissions will each receive a £100 gift card, and the first 20 eligible entries will receive free access to a GI-focused CPD course with The Webinar Vet.
In addition, entries submitted before 31st January will be entered into a draw to win a delegate ticket to SPVS Congress (Birmingham, 26–27th February), worth £675.
Entries close on 1st March.
Further information and case study form/guidelines available here: https://carusanimalhealth.com/giquest/prizes
Faecal calprotectin is a calcium-binding protein released into the gut lumen predominantly by neutrophils, and to a lesser extent by monocytes and macrophages, during intestinal inflammation.
Its presence in faeces reflects the degree of neutrophilic infiltration in the gut mucosa, making it a useful biomarker for identifying intestinal inflammation.
Faecal calprotectin lateral flow testing is already used in human health and included in the NICE guidelines for the management of inflammatory bowel disease (IBD)1.
Determining the underlying cause of chronic diarrhoea, vomiting and weight loss in cats and dogs can be complex, often requiring invasive procedures such as endoscopy or biopsy - both of which carry cost, risk, and sometimes practical limitations in general practice.
GIQuest is designed to offer a non-invasive, rapid alternative to support clinical decision-making.
Carus says that whilst not a replacement for histopathology, faecal calprotectin concentrations have been shown to correlate with disease severity in dogs and cats, as measured by tools such as the Canine Chronic Enteropathy Clinical Activity Index (CCECAI).2
New data from the University of Bristol Vet School appears to confirm the test’s ability to differentiate dogs with histologically-confirmed inflammatory enteropathy from healthy controls with high sensitivity (94%) and specificity (96%) using a score threshold of 3mg/kg.2
Carus says the test also performed well in cats, distinguishing those with inflammatory enteropathy from healthy controls with a specificity of 100% and sensitivity of 92%.
In addition, the test detected elevated calprotectin levels consistent with inflammatory gastroenteropathy in 25% of dogs receiving oral NSAIDs, which highlights its potential not only in long-term monitoring but also early in treatment when GI side effects may first emerge.
Jolian Howell of Carus Animal Health said: “Faecal calprotectin testing can provide additional clarity in a range of clinical scenarios.
"It is particularly useful when diagnosing and managing suspected inflammatory enteropathy or food related reactions and for monitoring or screening for GI side effects of oral non-steroidal anti-inflammatories in long term OA therapy regimes.”
The Bristol study also showed that dogs with food-responsive enteropathy had a significant drop in calprotectin concentrations following dietary change, reinforcing the test’s role in tracking treatment response.
Georgie Louca, Veterinary Business Manager for Carus Animal Health, added: ”By providing a measurable, visual indicator of intestinal inflammation, GIQuest also helps support client communication and can improve compliance during treatment or dietary trials.”
GIQuest is designed for use in practice, including during consultations, delivering colour-coded results in 15 minutes.
GIQuest is now available to veterinary practices across the UK and can be ordered through veterinary wholesalers NVS, Covetrus and MWI.
References